G1 Therapeutics, Inc. announced that the company has initiated a Phase II, single arm, open-label study of trilaciclib in patients with early-stage triple negative breast cancer designed to further investigate the role of trilaciclib in modulating the anti-tumor immune response.
[G1 Therapeutics, Inc.]
7992332
{7992332:DDDDDDDD}
apa
50
1
169593
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/